News
Evotec: Management stapelt höher
Tolle Neuigkeiten für Aktionäre: Evotec (WKN: 566480) hebt seine EBITDA-Prognose für 2019 an. Die Aktie reagiert merkwürdig.
Evotec verbessert seine Einschätzung nicht nur marginal, sondern
Qiagen: Hier braut sich was zusammen!
Die Aktie von Qiagen (WKN: A2DKCH) begab sich Ende letzten Jahres auf eine regelrechte Achterbahnfahrt. Dafür gab es auch gute Gründe, über die wir Sie hier auf sharedeals.de stets auf dem Laufenden
Qiagen: Hier braut sich was zusammen!
Die Aktie von Qiagen (WKN: A2DKCH) begab sich Ende letzten Jahres auf eine regelrechte Achterbahnfahrt. Dafür gab es auch gute Gründe, über die wir Sie hier auf sharedeals.de stets auf dem Laufenden
Cannabis-Roundup: Canopy Growth & Aurora Cannabis
Investoren strömen wieder in den Sektor. In den letzten Tagen konnten die Aktien von Canopy Growth (WKN: A140QA), Aurora Cannabis (WKN: A12GS7) oder Tilray (WKN: A2JQSC) stark hinzugewinnen.
Das
Agilent Collaborates with University Researchers Investigating Risk Factors for Eczema
Agilent Technologies Inc. (NYSE: A) is collaborating with researchers at two UK universities who are looking into the risk factors for atopic eczema (also known as atopic dermatitis), a chronic
Clinical trial demonstrated superior wound closure rates with PICO◊ compared to traditional NPWT in lower extremity ulcers1
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announces the publication of a new randomized controlled trial (RCT) which demonstrated that the use of PICO Single
Two Landmark Nature Publications use NanoString’s GeoMx Digital Spatial Profiling to Dissect Mechanisms of Response to Immunotherapy
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research, today announced the publication of two peer-reviewed studies using the GeoMx™
EOS imaging Reports Its Full Year 2019 Sales
Regulatory News:
EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - Eligible PEA - PME), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and
Clovis Oncology’s Rubraca® (rucaparib) Granted FDA Priority Review for Advanced Prostate Cancer
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) for Rubraca® (rucaparib)
Morphosys: Wer hätte das gedacht?
Morphosys-Aktien (WKN: 663200) verloren gestern im Handelsverlauf fast 23 Euro im Xetra-Handel. Ein so eklatanter Rutsch kam wohl auch für pessimistische Anleger überraschend.
Egal, was der
Morphosys: Wer hätte das gedacht?
Morphosys-Aktien (WKN: 663200) verloren gestern im Handelsverlauf fast 23 Euro im Xetra-Handel. Ein so eklatanter Rutsch kam wohl auch für pessimistische Anleger überraschend.
Egal, was der
Evotec: Es geht Schlag auf Schlag
Ausnahmsweise ist die von Evotec (WKN: 566480) im Rahmen seiner heutigen Pressemitteilungen kommunizierte hochkarätige Forschungspartnerschaft nur eine (positive) Randnotiz. Diesmal geht es primär
ICON Issues Financial Guidance for Full Year 2020
ICON plc (NASDAQ: ICLR), global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health
Ipsen Appoints Steven Hildemann, MD., PhD as Executive Vice President, Chief Medical Officer
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200113005846/en/
(Photo: Business Wire)
Ipsen (Euronext: IPN; ADR
Illumina to Announce Fourth Quarter and Fiscal Year 2019 Financial Results on Wednesday, January 29, 2020
Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for fourth quarter and fiscal year 2019 following the close of market on Wednesday, January 29, 2020.
On the same day, at
Illumina to Announce Fourth Quarter and Fiscal Year 2019 Financial Results on Wednesday, January 29, 2020
Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for fourth quarter and fiscal year 2019 following the close of market on Wednesday, January 29, 2020.
On the same day, at
Illumina to Announce Fourth Quarter and Fiscal Year 2019 Financial Results on Wednesday, January 29, 2020
Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for fourth quarter and fiscal year 2019 following the close of market on Wednesday, January 29, 2020.
On the same day, at
Illumina Announces New Sequencing System, Partnership with Roche and Software Suite to Accelerate Adoption of Genomics
Illumina, Inc. (NASDAQ: ILMN) further demonstrated its commitment to making genomics more accessible for the potential benefit of patients today with a series of technology and partnership
Illumina Announces New Sequencing System, Partnership with Roche and Software Suite to Accelerate Adoption of Genomics
Illumina, Inc. (NASDAQ: ILMN) further demonstrated its commitment to making genomics more accessible for the potential benefit of patients today with a series of technology and partnership
Illumina Announces New Sequencing System, Partnership with Roche and Software Suite to Accelerate Adoption of Genomics
Illumina, Inc. (NASDAQ: ILMN) further demonstrated its commitment to making genomics more accessible for the potential benefit of patients today with a series of technology and partnership
Illumina and Roche Partner to Broaden Patient Access to Genomic Testing
Illumina, Inc. (NASDAQ: ILMN), the global leader in DNA sequencing and array-based technologies, and Roche, a global pioneer in pharmaceuticals and diagnostics, today announced a 15-year
Illumina and Roche Partner to Broaden Patient Access to Genomic Testing
Illumina, Inc. (NASDAQ: ILMN), the global leader in DNA sequencing and array-based technologies, and Roche, a global pioneer in pharmaceuticals and diagnostics, today announced a 15-year
Illumina and Roche Partner to Broaden Patient Access to Genomic Testing
Illumina, Inc. (NASDAQ: ILMN), the global leader in DNA sequencing and array-based technologies, and Roche, a global pioneer in pharmaceuticals and diagnostics, today announced a 15-year
Lantheus Holdings Announces Senior Leadership Appointment
Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative
ICON plc to Present at 38th Annual J.P. Morgan Healthcare Conference and Issue Financial Guidance for Full Year 2020
ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health